Abcuro raised $66 million in a Series D to advance ulviprubart, an investigational monoclonal antibody for inclusion body myositis. The company said the round supports a registrational clinical study and aims to begin preparations for a trial launch in Q4 2026. Abcuro’s plan builds on subgroup insights from its Phase II/III MUSCLE study, following an overall primary-endpoint miss in the full population.